Quantcast
Last updated on April 23, 2014 at 12:08 EDT

Latest Tuberculosis treatment Stories

2013-08-06 08:35:53

A Recent Audit of Patient Records Finds That Physicians are Foregoing Treatment of Their HCV Patients Until New Agents Become Available, According to a New Report from BioTrends Research Group EXTON, Pa., Aug. 6, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that three-quarters of patients who have failed prior regimens, regardless of genotype, are not likely to re-treat their...

DNA Detection Breakthrough Could Lead To Improved Tuberculosis Treatments
2013-07-29 13:22:02

Brett Smith for redOrbit.com - Your Universe Online Minor mutations in DNA code can make for major malfunctions, and a breakthrough technique has allowed scientists to spot genetic changes with greater precision than ever. According to a new report in the journal Nature Chemistry, the new method can look at a specific DNA sequence and pull out a single mutation. "We've really improved on previous approaches because our solution doesn't require any complicated reactions or added...

2013-07-25 10:11:43

Low expression of immune response gene 'MIF' increased risk for TB A researcher from the Perelman School of Medicine at the University of Pennsylvania and colleagues have identified the genetic mutation in Africans with HIV that puts them at a much higher risk for tuberculosis (TB) infections. Africans have some of the highest rates of TB in the world, and it has long been suspected that genetic susceptibility plays a role. However, establishing candidate genes across populations to...

2013-07-05 11:10:05

The immune response to the bacterium that causes tuberculosis (TB) varies between patients of different ethnic origin, raising important implications for the development of tests to diagnose and monitor treatment for the disease, according to new research published today in the journal PLOS Pathogens. The study, led by researchers at Queen Mary, University of London, in collaboration with the Medical Research Council's National Institute for Medical Research (NIMR), analyzed the immune...

2013-07-02 11:06:13

People with tuberculosis (TB) in China often delay going to see a doctor for more than two weeks, finds research in BioMed Central's open access journal BMC Medicine. Reasons for this include a poor understanding of TB, increasing costs of treatment not covered by health insurance, and using traditional approaches first. Even after going to a clinic there were still delays in treatment, especially in rural areas, due to a lack of qualified medical staff. Worldwide TB remains a leading...

2013-05-28 16:25:42

Accomplished Global Health Leader brings development and international health expertise NEW YORK, May 28, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing better, faster-acting, and affordable TB treatments, announces the election of Debrework Zewdie, Ph.D. to its Board of Directors. Dr. Zewdie is a deeply accomplished global health leader, and brings significant expertise to the organization. "I've dedicated my career to...

2013-05-21 12:28:40

NEW YORK, May 21, 2013 /PRNewswire-USNewswire/ -- In a striking, unexpected discovery, researchers at Albert Einstein College of Medicine of Yeshiva University have determined that vitamin C kills drug-resistant tuberculosis (TB) bacteria in laboratory culture. The finding suggests that vitamin C added to existing TB drugs could shorten TB therapy, and it highlights a new area for drug design. The study was published today in the online journal Nature Communications. (Logo:...

2013-03-14 14:50:22

Models could improve the treatment of HIV patients in countries with limited resources Results of a study published online in the Journal of Antimicrobial Chemotherapy today (Thursday), demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. Crucially for patients in poorer countries, the models do not require the results of expensive drug resistance tests to make their predictions. The study also showed that the models...

2013-03-04 08:30:16

Former Johnson & Johnson Chairman of Pharmaceuticals brings global product development and commercialization expertise NEW YORK, March 4, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing better, faster-acting, and affordable TB treatments, announces the election to its Board of Directors of David Norton, former Company Group Chairman of Global Pharmaceuticals for Johnson & Johnson (J&J). Mr. Norton brings to TB Alliance...

2013-02-25 12:24:56

Global health expert and diplomat to lend skills, support to optimize new TB drug introductions WASHINGTON and NEW YORK, Feb. 25, 2013 /PRNewswire-USNewswire/ -- TB Alliance, a not-for-profit organization with the mission of developing new, improved, and affordable TB treatments, announces the election of Karl Hofmann, President and CEO of Population Services International (PSI), as President of the TB Alliance's Stakeholders Association (SHA), thereby assuming a seat on its Board of...